Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals reports positive CANYON-1 topline obesity data for CRB-913

Positive Impact 3 of 5 product/contract Written later

Corbus Pharmaceuticals announced positive topline results from its 16-week CANYON-1 Phase 1b trial of oral CRB-913 for obesity, showing statistically significant weight loss at all three doses, with the 60 mg dose producing a mean 5.0% weight loss at 12 weeks versus placebo. The data will be presented as a late-breaking abstract at ObesityWeek 2026, and the company plans to engage with the FDA and start a Phase 2 monotherapy study in the first half of 2027. The filing reports no revenue or profit figures, and the results come from a small early-stage trial with cross-trial safety comparisons that the company itself notes are not head-to-head.

Key points

  • 60 mg cohort (n=62) showed 5.0% mean weight loss at week 12 versus 0.0% for placebo (n=66), p<0.0001
  • Treatment discontinuations due to adverse events were 3.1% to 13.1% for CRB-913, versus 6.9% to 20.7% for approved oral GLP-1 drugs, per cross-trial comparison
  • Data to be presented at ObesityWeek 2026, November 14 to 17, 2026; Phase 2 monotherapy study expected to start in first half of 2027

The filing

CompanyCorbus Pharmaceuticals Holdings, Inc. (CRBP)
Form8-K, current report
Filed with the SECSep 14, 2026, 7:06 AM ET
Accession number0001193125-26-389829

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.